Clinical

This article highlights challenges in prior authorization and offers practical, experience-based strategies to streamline workflows, reduce delays, and improve patient access to necessary treatments.

This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.

Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.

A review updates MASH diagnosis and prognosis guidelines, highlighting noninvasive scores, imaging, and emerging therapies, plus lifestyle strategies to improve outcomes.

Vishal A. Patel, MD, explains that delayed skin cancer diagnoses contribute to more advanced disease and poorer outcomes in patients with darker skin.

Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.

Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective patient management and support.

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient support and effective communication.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

Catchment areas, access, and partnerships influence diversity in oncology trials, Amir Fathi, MD, explains at a Boston IVBM panel.

Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.

To protect patients, the FDA will restrict ingredients in unapproved compounded GLP‑1 drugs and crack down on misleading marketing.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

A deep-learning serial CT response score outperformed conventional imaging measures in predicting OS for patients with advanced NSCLC treated with ICIs.

City St. George’s researchers identified 9 genetic signatures and epigenetic changes driving lapatinib resistance in HER2-positive breast cancer.

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.